Showing 1301-1310 of 1644 results for "".
- Investigational Intradiscal Injection Improved Pain Associated with Lumbar Disc Herniationhttps://practicalneurology.com/news/investigational-intradiscal-injection-improved-pain-associated-with-lumbar-disc-herniation/2470528/People treated with experimental product SI-6603 (condoliase; Ferring Pharmaceuticals, Parsippany, NJ; Seikagaku, Tokyo, Japan) by a single intradiscal injection showed improvements in the radicular leg pain associated with their lumbar disc herniation (LDH). Early response data from a phase 3 st
- Antipsychotic Use Associated with Multiple Adverse Outcomes in Dementia Patientshttps://practicalneurology.com/news/antipsychotic-use-associated-with-multiple-adverse-outcomes-in-dementia-patients/2470475/Antipsychotic use in adults with dementia was associated with increased risks of stroke, venous thromboembolism, myocardial infarction, heart failure, fracture, pneumonia, and acute kidney injury, according to study results published in The BMJ. Previous studies established increased ris
- Meta-Analysis Identifies Association Between Personality Traits and Dementia Riskhttps://practicalneurology.com/news/meta-analysis-identifies-association-between-personality-traits-and-dementia-risk/2470364/Specific personality traits, including neuroticism, negative affect, low conscientiousness, and low extraversion, were associated with an increased risk for a dementia diagnosis, according to research published in Alzheimer’s & Dementia. Conversely, positive affect and higher c
- In Utero Exposure to Ocrevus Not Associated with Elevated Adverse Outcomes in Pregnancyhttps://practicalneurology.com/news/in-utero-exposure-to-ocrevus-not-associated-with-elevated-adverse-outcomes-in-pregnancy/2470314/In a study of the largest available dataset for pregnancy outcomes for an anti-CD20 monoclonal antibody therapy, in utero exposure to Ocrevus (ocrelizumab; Genentech, South San Francisco, CA), a medication used to treat multiple sclerosis (MS), was not associated with an elevated risk of preterm
- Vaccinations Not Associated with Multiple Sclerosis Flare-ups According to New Studyhttps://practicalneurology.com/news/vaccinations-not-associated-with-multiple-sclerosis-flare-ups-according-to-new-study/2470300/According to results from a nationwide French study published in JAMA Neurology, there was no association between vaccinations and incidence of severe multiple sclerosis (MS) flare-ups requiring hospitalization. The findings were consistent regardless of age range, whether the participan
- Researchers Confirm 4 Genes Associated with Increased Risk of Developing PMLhttps://practicalneurology.com/news/researchers-confirm-4-genes-associated-with-an-increased-risk-of-developing-pml-researchers-confirm-4-genes-associated-with-an-increased-risk-of-developing-pml/2470291/Researchers have identified 4 genes associated with an increased risk of developing progressive multifocal leukoencephalopathy (PML) in patients taking 99 different PML-linked drugs for a variety of conditions, including multiple sclerosis (MS), blood cancers, and rheumatoid arthritis. This study
- Muscular Dystrophy Association Announces the Start of 30 Days of Strength Campaignhttps://practicalneurology.com/news/mda-announces-the-start-of-30-days-of-strength-campaign/2470289/The Muscular Dystrophy Association (MDA) has announced the start of its 30 Days of Strength campaign for September, which is National Muscular Dystrophy Awareness Month. Throughout the month, the MDA will collaborate with influencers and community leaders, including Nyheim Hines, running back for
- New FDA Filing for Potential Drug To Treat Chorea Associated with Huntington Diseasehttps://practicalneurology.com/news/new-fda-filing-for-potential-drug-to-treat-chorea-associated-with-huntington-disease/2470090/The Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for valbenazine (Ingrezza; Neurocrine Biosciences, San Diego, CA) as a treatment for chorea associated with Huntington disease (HD). The sNDA filing contained data from the KINECT-HD phase 3 study (
- American Heart Association Releases Statement on Cannabis and Brain Healthhttps://practicalneurology.com/news/american-heart-association-releases-statement-on-cannabis-and-brain-health/2469820/A new American Heart Association (AHA) scientific statement published in Stroke states that although there is a perception that cannabis is harmless, there is some scientific evidence challenging that belief. The statement also notes there are many unanswered questions about its impact on brain h
- Clinical Implications of Pimavanserin Association With Mortality in Parkinson Disease Psychosishttps://practicalneurology.com/news/clinical-implications-of-pimavanserin-association-with-mortality-in-parkinson-disease-psychosis/2469708/It has been suggested that use of pimavanserin for the treatment of Parkinson disease (PD) psychosis symptoms is associated with higher mortality rates. The FDA found these rates unsimilar to that seen with other atypical antipsychotics, and both carry a black-box warning as a result. This has be